Jonas Oldgren

List of Publications by Year
in descending order

113 papers	38,651 citations	47006 47 h-index	23533 111 g-index
115 all docs	115 docs citations	115 times ranked	24178 citing authors

#	Article	IF	Citations
1	Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 2009, 361, 1139-1151.	27.0	9,839
2	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
3	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2021, 42, 373-498.	2.2	5,583
4	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
5	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal, 2018, 39, 1330-1393.	2.2	1,576
6	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. New England Journal of Medicine, 2017, 377, 1513-1524.	27.0	1,099
7	Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation. Circulation, 2011, 123, 2363-2372.	1.6	1,035
8	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2015, 17, 1467-1507.	1.7	951
9	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
10	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 2013, 15, 625-651.	1.7	721
11	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace, 2021, 23, 1612-1676.	1.7	494
12	Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. European Heart Journal, 2011, 32, 2781-2789.	2.2	487
13	Concomitant Use of Antiplatelet Therapy with Dabigatran or Warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Trial. Circulation, 2013, 127, 634-640.	1.6	447
14	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, The, 2016, 387, 2302-2311.	13.7	389
15	Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial. Circulation, 2012, 125, 669-676.	1.6	348
16	Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation. Circulation, 2012, 125, 1605-1616.	1.6	346
17	Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation. Circulation, 2014, 129, 961-970.	1.6	346
18	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. European Heart Journal, 2016, 37, 1582-1590.	2.2	329

#	ARTICLE	IF	CITATIONS
19	Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries. Circulation, 2014, 129, 1568-1576.	1.6	324
20	Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. American Heart Journal, 2009, 157, 805-810.e2.	2.7	298
21	Biomarkers in atrial fibrillation: a clinical review. European Heart Journal, 2013, 34, 1475-1480.	2.2	246
22	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. Lancet, The, 2016, 388, 1161-1169.	13.7	216
23	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. European Heart Journal, 2017, 38, ehw058.	2.2	203
24	The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace, 2018, 20, 1231-1242.	1.7	194
25	Risks for Stroke, Bleeding, and Death in Patients With Atrial Fibrillation Receiving Dabigatran or Warfarin in Relation to the CHADS_2 Score: A Subgroup Analysis of the RE-LY Trial. Annals of Internal Medicine, 2011, 155, 660.	3.9	181
26	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. European Heart Journal, 2013, 34, 1670-1680.	2.2	175
27	Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. European Heart Journal, 2018, 39, 1726-1735a.	2.2	133
28	Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events. Circulation, 2017, 136, 1183-1192.	1.6	128
29	Apixaban compared to heparin/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial. European Heart Journal, 2018, 39, 2959-2971.	2.2	126
30	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace, 2016, 18, 37-50.	1.7	121
31	Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex. Circulation, 2022, 145, 242-255.	1.6	118
32	Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. American Heart Journal, 2015, 170, 1151-1160.	2.7	99
33	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. Europace, 2018, 20, 395-407.	1.7	95
34	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 142	2.2	92
35	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. European Heart Journal, 2020, 41, 4037-4046.	2.2	90
36	Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation. Clinical Chemistry, 2017, 63, 152-164.	3.2	79

#	Article	IF	Citations
37	Effects of dabigatran according to age in atrial fibrillation. Heart, 2017, 103, 1015-1023.	2.9	78
38	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. Circulation, 2016, 134, 1697-1707.	1.6	76
39	Registry-Based Pragmatic Trials in Heart Failure: Current Experience and Future Directions. Current Heart Failure Reports, 2017, 14, 59-70.	3.3	72
40	All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart, 2016, 102, 926-933.	2.9	70
41	Design and Rationale of the <scp>RE‐DUAL PCI</scp> Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clinical Cardiology, 2016, 39, 555-564.	1.8	65
42	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. European Heart Journal, 2019, 40, 1553-1562.	2.2	62
43	Direct or subacute coronary angiography in out-of-hospital cardiac arrest (DISCO)â€"An initial pilot-study of a randomized clinical trial. Resuscitation, 2019, 139, 253-261.	3.0	58
44	An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. American Heart Journal, 2005, 149, 619-626.	2.7	56
45	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2018, 72, 255-267.	2.8	56
46	Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients. European Heart Journal, 2007, 28, 699-704.	2.2	55
47	Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden. European Heart Journal, 2013, 34, 177-183.	2.2	55
48	Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy. Heart, 2014, 100, 1193-1200.	2.9	47
49	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. American Heart Journal, 2017, 190, 94-103.	2.7	42
50	Effects of 6â€‰weeks of treatment with dapagliflozin, a sodiumâ€glucose coâ€transporterâ€2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: A randomized, placeboâ€controlled, exploratory study. Diabetes, Obesity and Metabolism, 2021, 23, 1505-1517.	4.4	42
51	Incidence and outcome of myocardial infarction treated with percutaneous coronary intervention during COVID-19 pandemic. Heart, 2020, 106, 1812-1818.	2.9	40
52	Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA Consensus Conference. Europace, 2021, 23, 329-344.	1.7	38
53	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. European Heart Journal, 2008, 29, 315-323.	2.2	37
54	Dabigatran etexilate and reduction in serum apolipoprotein B. Heart, 2016, 102, 57-62.	2.9	34

#	ARTICLE	IF	CITATIONS
55	Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG—Short- and long-term survival. American Heart Journal, 2018, 200, 90-95.	2.7	34
56	Apixaban compared with parenteral heparin and/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: Rationale and design of the EMANATE trial. American Heart Journal, 2016, 179, 59-68.	2.7	32
57	Association Between the Use of Fondaparinux vs Low-Molecular-Weight Heparin and Clinical Outcomes in Patients With Non—ST-Segment Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2015, 313, 707.	7.4	31
58	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. Thrombosis Research, 2016, 139, 77-81.	1.7	29
59	Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation: study protocol for a registry-based randomised controlled trial. Trials, 2017, 18, 581.	1.6	28
60	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PLoS ONE, 2017, 12, e0181000.	2.5	28
61	Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM trial. European Heart Journal, 2007, 28, 692-698.	2.2	27
62	Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation. Open Heart, 2017, 4, e000682.	2.3	27
63	Design of DISCO—Direct or Subacute Coronary Angiography in Out-of-Hospital Cardiac Arrest study. American Heart Journal, 2018, 197, 53-61.	2.7	26
64	Fibrinolytic therapy and bleeding complications: risk predictors from RIKS-HIA. Heart, 2010, 96, 1451-1457.	2.9	25
65	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, f50-f60.	3.0	24
66	Risk of ischemic stroke and utility of CHA$_2$DS$_2$-VASc score in women and men with atrial fibrillation. Clinical Cardiology, 2019, 42, 1003-1009.	1.8	23
67	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 216-226.	3.0	23
68	Systematic Coronary Risk Evaluation estimated risk and prevalent subclinical atherosclerosis in coronary and carotid arteries: A population-based cohort analysis from the Swedish Cardiopulmonary Bioimage Study. European Journal of Preventive Cardiology, 2021, 28, 250-259.	1.8	22
69	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. Pharmacogenomics, 2016, 17, 1425-1439.	1.3	21
70	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. Europace, 2016, 18, 973-978.	1.7	19
71	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Cardiovascular Research, 2022, 118, 2112-2123.	3.8	18
72	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. Journal of the American Heart Association, 2019, 8, e010107.	3.7	17

#	Article	IF	Citations
73	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. Journal of Thrombosis and Haemostasis, 2021, 19, 2726-2737.	3.8	17
74	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. Europace, 2017, 19, 1630-1636.	1.7	16
75	The utility of coagulation activity for prediction of risk of mortality and cardiovascular events in guideline-treated myocardial infarction patients. Upsala Journal of Medical Sciences, 2017, 122, 224-233.	0.9	15
76	Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e008349.	3.9	15
77	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time—A RE-LY trial analysis. American Heart Journal, 2018, 198, 169-177.	2.7	14
78	Antithrombotic therapy after myocardial infarction in patients with atrial fibrillation undergoing percutaneous coronary intervention. European Heart Journal - Cardiovascular Pharmacotherapy, 2018, 4, 36-45.	3.0	14
79	Effects of DAPAgliflozin on CARDiac substrate uptake, myocardial efficiency, and myocardial contractile work in type 2 diabetes patients—a description of the DAPACARD study. Upsala Journal of Medical Sciences, 2019, 124, 59-64.	0.9	14
80	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. Journal of Thrombosis and Haemostasis, 2020, 18, 2287-2295.	3.8	14
81	Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease. Thrombosis and Haemostasis, 2004, 91, 381-387.	3.4	13
82	Effects of sauna bath on heart failure: A systematic review and meta-analysis. Clinical Cardiology, 2018, 41, 1491-1501.	1.8	13
83	Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal, 2019, 212, 13-22.	2.7	13
84	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post–PCI in Patients With Atrial Fibrillation and Diabetes. JACC: Cardiovascular Interventions, 2019, 12, 2346-2355.	2.9	13
85	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or) Tj ETQq1 1 0.7843	1.6	13
86	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. Europace, 2020, 22, 870-877.	1.7	13
87	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. Europace, 2022, 24, 1844-1871.	1.7	11
88	Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?. Internal and Emergency Medicine, 2013, 8, 673-680.	2.0	10
89	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. Open Heart, 2018, 5, e000800.	2.3	9
90	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. JACC: Cardiovascular Interventions, 2019, 12, 1553-1561.	2.9	9

#	Article	IF	Citations
91	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. JACC: Cardiovascular Interventions, 2019, 12, 2331-2341.	2.9	8
92	Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial. Drugs, 2020, 80, 995-1005.	10.9	8
93	Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Cardiovascular Research, 2022, 118, 295-304.	3.8	8
94	Weight gain and blood pressure. Journal of Hypertension, 2020, 38, 387-394.	0.5	7
95	Risk markers of incident atrial fibrillation in patients with coronary heart disease. American Heart Journal, 2021, 233, 92-101.	2.7	7
96	Serum Neurofilament Light Chain in Patients With Atrial Fibrillation. Journal of the American Heart Association, 0, , .	3.7	7
97	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model. American Heart Journal, 2022, 251, 13-24.	2.7	6
98	Xa inhibition and coagulation activityâ€"the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals. American Heart Journal, 2008, 155, 493.e1-493.e8.	2.7	5
99	Evaluation of the Age, Biomarkers, and Clinical Historyâ€"Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. JAMA Network Open, 2020, 3, e2015943.	5.9	5
100	Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCIÂTrial. JACC: Cardiovascular Interventions, 2021, 14, 768-780.	2.9	5
101	Effects of apixaban compared with warfarin as gain in event-free time â€" a novel assessment of the results of the ARISTOTLE trial. European Journal of Preventive Cardiology, 2020, 27, 1311-1319.	1.8	4
102	Post-resuscitation myocardial dysfunction in out-of-hospital cardiac arrest patients randomized to immediate coronary angiography versus standard of care. IJC Heart and Vasculature, 2020, 27, 100483.	1.1	4
103	The ABC risk score for patients with atrial fibrillation â€" Authors' reply. Lancet, The, 2016, 388, 1980-1981.	13.7	3
104	Low Walking Impairment Questionnaire score after a recent myocardial infarction identifies patients with polyvascular disease. JRSM Cardiovascular Disease, 2019, 8, 204800401984197.	0.7	2
105	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2020, 75, 238-240.	2.8	2
106	The effect of sex on the efficacy and safety of dual antithrombotic therapy with dabigatran versus triple therapy with warfarin after <scp>PCI</scp> in patients with atrial fibrillation (a <scp>REâ€DUAL) Tj ETQq0 0 0 rgBT /Overlock 10 T Cardiology, 2021, 44, 1002-1010.	1.8	2
107	Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2021, 81, 353-360.	1.2	2
108	Response to Letter Regarding Article, â€œEfficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation: A RE-LY (Randomized) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 57 Td		

#	Article	IF	Citations
109	Response by Oldgren and Sundström to Letter Regarding Article, "Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study". Circulation, 2018, 137, 2313-2313.	1.6	1
110	Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI. American Journal of Medicine, 2020, 133, 1302-1312.	1.5	1
111	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. PLoS ONE, 2020, 15, e0226259.	2.5	1
112	Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis. Journal of Thrombosis and Thrombolysis, 2022, 53, 74-82.	2.1	1
113	Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a <i>post hoc</i> analysis of the ATHENA trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 363-371.	3.0	0